Probiotics for Gastrointestinal and Liver Diseases: An Updated Review of the Published Literature / Francis E. Dailey, Erica P. Turse, Brett Rossow, Vanessa K. Kuwajima, Veysel Tahan
Background: Probiotics can be viewed as biological agents that modify the intestinal microbiota and certain cytokine profiles, which can lead to an improvement in certain gastrointestinal diseases, including diarrhea, inflammatory bowel disease, and liver disease. Discussion: Consumption of probiotics in their various forms, including yogurt, functional foods, and dietary supplements, is frequently encountered worldwide. Often, however, the correct prescription of these agents is dampened due to a lack of knowledge of the scientific evidence and the different presentations and microbial compositions of the currently available probiotic options. Here, we provide an up-to-date review of the evidence of probiotics in the prevention and treatment of various gastrointestinal diseases. Objective: Consumption of probiotics in their various forms, including yogurt, functional foods, and dietary supplements, is frequently encountered worldwide. Often, however, the correct prescription of these agents is dampened due to a lack of knowledge of the scientific evidence and the different presentations and microbial compositions of the currently available probiotic options. Methods/Results: Here, we provide an up-to-date review of the evidence of probiotics in the prevention and treatment of various gastrointestinal diseases. Conclusion: While not efficacious in every disease process studied, probiotics have demonstrated some benefit in several specific gastrointestinal and liver diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Endocrine, metabolic & immune disorders, drug targets - 19(2019), 5, Seite 22 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dailey, Francis E. [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (22 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011142421 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011142421 | ||
| 003 | DE-627 | ||
| 005 | 20231128152002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011142421 | ||
| 035 | |a (KFL)prod_DARH_.63F19237A353FE7CFA809D51F04F5322E7EA3877 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Dailey, Francis E. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Probiotics for Gastrointestinal and Liver Diseases: An Updated Review of the Published Literature |c Francis E. Dailey, Erica P. Turse, Brett Rossow, Vanessa K. Kuwajima, Veysel Tahan |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (22 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Probiotics can be viewed as biological agents that modify the intestinal microbiota and certain cytokine profiles, which can lead to an improvement in certain gastrointestinal diseases, including diarrhea, inflammatory bowel disease, and liver disease. Discussion: Consumption of probiotics in their various forms, including yogurt, functional foods, and dietary supplements, is frequently encountered worldwide. Often, however, the correct prescription of these agents is dampened due to a lack of knowledge of the scientific evidence and the different presentations and microbial compositions of the currently available probiotic options. Here, we provide an up-to-date review of the evidence of probiotics in the prevention and treatment of various gastrointestinal diseases. Objective: Consumption of probiotics in their various forms, including yogurt, functional foods, and dietary supplements, is frequently encountered worldwide. Often, however, the correct prescription of these agents is dampened due to a lack of knowledge of the scientific evidence and the different presentations and microbial compositions of the currently available probiotic options. Methods/Results: Here, we provide an up-to-date review of the evidence of probiotics in the prevention and treatment of various gastrointestinal diseases. Conclusion: While not efficacious in every disease process studied, probiotics have demonstrated some benefit in several specific gastrointestinal and liver diseases | ||
| 700 | 1 | |a Turse, Erica P. |e verfasserin |4 aut | |
| 700 | 1 | |a Rossow, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Kuwajima, Vanessa K. |e verfasserin |4 aut | |
| 700 | 1 | |a Tahan, Veysel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Endocrine, metabolic & immune disorders, drug targets |d Sharjah : Bentham Science Publ., 2006 |g 19(2019), 5, Seite 22 |h Online-Ressource |w (DE-627)KFL000040738 |w (DE-600)2254157-3 |w (DE-576)273890999 |x 2212-3873 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:5 |g pages:22 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5303&volume=19&issue=5&spage=549 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 5 |h 22 | ||